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THEstudy ofthe mechanism oftheagar-binding reaction-a newprocedure for
the diagnosis of cancer-has raised certain problems and it is hoped that their
elucidationmight throw freshlight upon the role ofpolysaccharides in the biology
ofneoplasticgrowth (Csabaand T&6, 1958 ; Csaba, Tbr;j and Kiss, 1959a, 1959b).
Heparin, contained in the serum, has been found to be an important factor in
making the reaction positive or negative. Immune substances, produced by the
organism in the proliferative stage of tumours, are in our opinion responsible for
the positivity of the reaction, while heparin-by gaining ascendancy over the
lipoproteins in the terminalphase oftumour-bearingsubjects-causes the reaction
to become neagative (Fig. 1). By way of hypothesis, it was suggested in our
publication concerning the details of the mechanism of the agar-binding reaction
(Csaba et al., 1959) that the positivity of the reaction in the incipient phase of
neoplastic growths was due to the predominance of serum lipoproteins arising
from the tumours, or-in other words-that the demonstration of lipoproteins
and the consequentpositivity ofthe reaction were due to the fact that the amount
ofheparin was reduced. By artificially inhibiting the action ofheparin in in vitro
experiments we succeeded in turning the negative reaction given by the serum
ofhealthy individuals into apositive one. Therefore we feltjustified ininstituting
investigations into the role ofheparinoid substances, particularly as the problem
ofthe correlation betweenlipoproteins and tumours seems to have beensufficiently
elucidated (Barclay et al., 1957 ; Greenstein, 1954 ; Heiger, 1957 ; Holsti, 1958 ;
Homburger and Fishmann, 1953 ; Rapport, et al., 1958 ; Waterman, 1953).
A few reports are available in respect ofthe role ofheparinoid substances. It was,
for instance, observedby Panizzari andVegeto (1958) that the activity ofheparin
in the serum diminished after the implantation of the Walker tumour. Several
reports contain data concerninghighglucuronidaseactivity observable in tumours
(Greenstein, 1945 ; Hamer, 1953). It is claimed by Kizer and McKoy (I959) that
glucosamine, one of the most important structural components of heparin, is
synthesized by homogenates of the Walker tumour from hexose 6-phosphate and
glutamine.
Our present experiments were based on the notion that the amount ofhepari-
noid substances contained in the serum becomes less during the proliferation of
tumour cells, presumably because these substances are used up by the growing
tumour. Accordingly, theexperiments were started to cover two lines ofapproach:
1. We wanted to ascertain the effect of heparin and its components on tumour
growth and the survival ofinoculated animals ; 2. in iiitro and in vivoexperimentsEFFECT OF HEPARIN ON TUMOUR GROWTH 363
to determine the effect ofheparin-binding substances on the growth and viability
of tumours.
The present paper deals with the effects produced by heparin and its compo-
nents.
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FIG. I.-Correlation between the respective systems of lipids-antilipids and mucopolysac- charides-antixnucopolysaccharides, and its effect on the result of the agar-binding reaction.
The amount oflipids increases (shade lines) or that of the heparinoids decreases (squares) in the incipient phase of tumours.
METHOD
We studied the effect ofheparinoid components on 220 tumour-bearing mice.
Their average bodyweight was 20 g. The test animals-white and sand-coloured
males and females-were taken from the stock ofthe National Institute of Public
Health, Budapest. Transplanting Ehrlich ascites tumour into the mice, we used
doses of 0-05 ml. for subcutaneous injections, i.e. approximately 60,000 cells
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per rnLM.3 the dose for intraperitoneal injections was likewise 0-05 ml. but the
ascitic fluid was first diluted at the ratio I : 10, so that the number of cells was
approximately 6000 per MM.3 in these cases. These doses were occasionally
modified and are indicated in the tables. Low doses had the purpose ofprolonging
the tests so that the differences between experimentals and controls were more
conspicuous.
The animals were treated with the subcutaneous administration of Heparin
pulvis (Richter-80 I.U./mg.), d-glucuronic acid (Fluka) and a, d-glucosamine
(Light) preparations. The daily doses of these substances were dissolved in I ml.
of physiological saline. Tumour-bearing controls received a daily dose of I ml.
of physiological saline, injected subcutaneously. We also used controls treated
withglueuronic acid, glucosamine and heparinoid substances but without tumour
injection. Other than the heparinoids to which the animals succumbed, the other
substances showed no effect.
RESULTS
The effect of glucuronic acid and glucosamine on the survival of tumour-
bearing animals is shown in Table 1.
DISCUSSION
It was shown by the experiments that glueuronic acid, in daily doses varying
between 5 mg. and 30 mg., invariably promoted the destruction of tumour-
bearing animals in all groups, but failed to do any harm to non-tumour bearing
controls. It therefore seems justified to attribute the observed effects to the
presence of tumours as neoplastic growth was always more marked in treated
than in non-treated animals. The effect of glucosamine appeared to be similar
to, although less conspicuous than, that of glucuronic acid. That the observed
effect must be principally due to glucuronic acid was strikingly demonstrated by
the experiment in which bothglucuronic acid andglucosamine were administered :
their combined effect was in no way different from the effect observed in the
animals which had received glucuronic acid alone.
That we were right in using only small amounts of ascites for the transfers is
convincingly shownby theexperimental results. Althoughhigh doses ofglucuronic
acid were administered to the members of group 7, the difference between experi-
mentals and controls was very slight in this group where the transplanted ascites
had not been diluted. Survival of the controls was considerably longer in group 6
while the survival of the experimentals was 25 per cent shorter than in group 7.
Differences are most pronounced in the intraperitoneal groups 5 and 8 where the
time of survival of the controls is very long and even reaches that of subcutane-
ously inoculated animals.
It was found by Heilbrunn (1956), Bala'zs and Holmgren (1947), and also by
Koenig (1955) that whole heparin inhibits tumour growth. We failed to observe
this effect because the doses ofheparin applied in our experiments induced large
haematomas and led to a quick death of the animals. At any rate, even if we
accept the statement of these authors we must emphasize that their claim calinot
apply to the structural components ofheparin which, far from inhibiting tumours,
promote neoplastic growth and so hasten the death of the animals. The expet-i-365 EFFECT OF HEPARIN ON TUMOUR GROWTH
TABLE I.-gffect of Olucuronic Acid and Glucosamine on the, Survival of
Tumour-bearing Mice,
Average
survival
days
Shortening
ofsurvival
(Percent)
Route of Treatment
administration doses/mouse
S.C. Heparin
10 mg./day
9.1 Control
Number of
Group animals
1 20
10
2 10
10
10
20
20
Colour,
sex
White, F.
Observations
5th-8th day exit.
35-0
36- 8
33- 3
32- 9
26-3
27
- 1
33- 3
29- 6
32- 9
27-0
29- 8
33-4
23
- 2
lVhite, F.
Sand, M.
31 .1 9 31
9 . 31 9
.31 319
S.C. Control
91- 9 9
31 51 9 .
Glue. ae.
10 mg./day
9p Ditto
S.C. Control
9 51 Gluc. ae.
10 mg./day
S.C. Control
519 Gluc. ae.
10 mg./day
99 Ditto
I.P. Control
9 9 Gluc. ae.
5 mg./day
20-0
18-6
11- 5
17- 8
9-6
30- 6
3 10 Sand, F.
lo 99 .31
4 10
10
10
Sand, F.
9 9 ; 3-
!-9 pp
5 10 White, F.
10 99 99
5 White, F. I.P. Control 20- 0 Inoculated with
undiluted ascites.
15-0 25-0
13-3 Inoculated with
undilutedascites.
11.0 17-3
6
5 1-. Gluc. ac.
30 mg./day
9 9 ) 9
7 10 White, F. I.P. Control
10 .9- Glue. ac.
30 mg./day
9 9 9 .
8 10 Wliite, F. I.P.
10 99 I'll 99
Control
Glucos. 2 mg.
+glue. ac. 5
mg-/day
33-4
23
- 8
Identical with con-
28- 8 trol ofgroup 5.
9 10 White, F. Glue. ac. 30
mg./day for
30 days
Received no tu-
mour ; no effect
observed.
mental results raise theproblem : is thehigher level of serum mucoids in the blood
of tumour-bearing individuals and test animals with well-advanced tumours to
be regarded as a consequence ofneoplastic growth (Almquist and Lansing, 1957 ;
Homburger and Fishmann, 1953 Rottimer, Levy and Conte, 1958 ; Shetlar
et al., 1949 ; Weimer et al., 1957 Winzler and Smyth, 1948)-from the disinte-
gration of mast cells etc.-or as the causative agent of tumours? There seems to
be no sharp boundary between cause and effect : both seem to participate in the
maintenance of the vicious circle in malignant disease.
It was not possible to resolve these problems on the evidence of the present
experiments. Therefore, additional experiments-in vitro and in vivo-have been
performed and the results form the subject of a subsequent publication.366 G. CSABA, CECILIA HORVATH AND TH. ACS
SUMMARY
The effect of heparin and its components on the survival of tumour-bearing
animals has been examined. The experiments, as described in the paper, show
that glucuronic acid or glucosamine and glucuronic acid-if administered in
protracted doses-shorten the life of tumour-bearing mice.
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